NCT03571607View on ClinicalTrials.gov

A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2018

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.

Trial Locations (8)

457-8511

Daido Clinic, Nagoya

721-0927

Nippon Kokan Fukuyama Hospital, Fukuyama

721-8511

Fukuyama City Hospital, Fukuyama

210-0013

Kawasaki Municipal Hospital, Kawasaki

382-8577

Nagano Prefectural Shinshu Medical Center, Suzaka

812-0025

Medical Co.LTA PS Clinic, Fukuoka

813-0017

Fukuoka Children's Hospital, Fukuoka

860-0008

National Hospital Organization Kumamoto Medical Center, Kumamoto

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03571607 - A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years. | Biotech Hunter | Biotech Hunter